血必净注射液治疗急性非ST段抬高型心肌梗死的临床观察

发布时间：2018-05-21 08:49

本文选题：血必净注射液 + 急性非ST段抬高型心肌梗死　；参考：《中国药房》2017年23期

【摘要】：目的:探讨血必净注射液对急性非ST段抬高型心肌梗死(NSTEMI)患者的炎症因子、氧化应激水平和血栓风险的影响以及用药安全性。方法:选取2015年5月-2016年8月我院收治的NSTEMI患者130例作为研究对象,按照随机数字表法分为对照组和观察组,各65例。对照组患者给予降压、降脂、抗凝和抗血小板等常规治疗;观察组患者在对照组基础上给予血必净注射液50 m L,ivgtt,q12 h。两组患者均连续治疗1周。观察两组患者治疗前后血清炎症因子[肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、IL-10和超敏C反应蛋白(hs-CRP)]、超氧化物歧化酶(SOD)、丙二醛(MDA)、基质金属蛋白酶9(MMP-9)、血小板集聚率和纤维蛋白原水平,并记录治疗过程以及治疗后1个月内MACE和出血事件的发生情况。结果:治疗前,两组患者炎症因子、SOD、MDA、MMP-9、血小板集聚率和纤维蛋白原水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者TNF-α、IL-6、hs-CRP、血小板聚集率和纤维蛋白原水平均明显降低,IL-10水平明显升高,且观察组患者上述指标改善程度均明显优于对照组。两组患者SOD和MMP-9水平均明显升高,MDA水平明显降低;观察组患者SOD水平明显高于对照组,MDA水平明显低于对照组,但MMP-9水平明显低于对照组,差异均有统计学意义(P0.05)。两组患者的MACE发生率(16.92%vs.20.00%)和出血事件发生率(4.62%vs.7.69%)比较,差异均无统计学意义(P0.05)。结论:血必净注射液治疗NSTEMI疗效显著,可有效抑制患者的炎症和氧化应激水平,降低血栓形成风险,且安全性较高。
[Abstract]:Objective: to investigate the effects of Xuebijing injection on inflammatory factors, oxidative stress and thrombus risk in patients with acute non-ST-segment elevation myocardial infarction (AMI). Methods: one hundred and thirty patients with NSTEMI from May 2015 to August 2016 were randomly divided into two groups: control group and observation group. The patients in the control group were treated with antihypertensive, lipid-lowering, anticoagulant and anti-platelet therapy, and the patients in the observation group were treated with Xuebijing injection 50 mL iv GTT q12 h on the basis of the control group. The patients in both groups were treated continuously for 1 week. Before and after treatment, serum inflammatory factors (TNF- 伪, IL-6, IL-10 and hs-CRP), superoxide dismutase (SOD), malondialdehyde (MDA), matrix metalloproteinase-9 (MMP-9), platelet aggregation and fibrinogen levels were observed in both groups. The course of treatment and the occurrence of MACE and bleeding events within 1 month after treatment were recorded. Results: before treatment, there was no significant difference in the levels of MDAMDA-9, platelet aggregation and fibrinogen between the two groups (P 0.05). After treatment, the levels of TNF- 伪 IL-6hs-CRP, platelet aggregation and fibrinogen were significantly decreased in both groups, and the improvement of the above indexes in the observation group was significantly better than that in the control group. The levels of SOD and MMP-9 in the two groups were significantly higher than those in the control group, and the levels of SOD in the observation group were significantly higher than those in the control group, but the MMP-9 level was significantly lower than that in the control group (P 0.05). There was no significant difference between the two groups in the incidence of MACE (16.92 vs 20.00) and the incidence of bleeding events (4.62% vs 7.69). Conclusion: Xuebijing injection is effective in the treatment of NSTEMI. It can effectively inhibit inflammation and oxidative stress and reduce the risk of thrombosis.
【作者单位】：漯河市中心医院药剂科;漯河市中心医院呼吸内科;漯河市中心医院心内科;
【分类号】：R542.22

【相似文献】